Patents Issued in November 14, 2017
  • Selective glycosidase inhibitors and uses thereof
    Patent number: 9815861
    Abstract: The invention provides compounds with enhanced permeability for selectively inhibiting glycosidases, prodrugs of the compounds, and pharmaceutical compositions including the compounds or prodrugs of the compounds. The invention also provides methods of treating diseases and disorders related to deficiency or overexpression of O-GlcNAcase, accumulation or deficiency of O-GlcNAc.
    Type: Grant
    Filed: December 11, 2015
    Date of Patent: November 14, 2017
    Assignees: Alectos Therapeutics, Inc., Merck Sharp & Dohme Corp.
    Inventors: Ramesh Kaul, Ernest J. McEachern, Changwei Mu, Harold G. Selnick, David J. Vocadlo, Yaode Wang, Zhongyong Wei, Yuanxi Zhou, Yongbao Zhu
  • Polymorphs of LNnT
    Patent number: 9815862
    Abstract: A crystalline LNnT polymorph IV, characterized in that it displays X-ray powder diffraction reflections, based on a measurement using CuK? radiation, at 8.16, 15.41, 39.14, 23.77, 7.77 and 31.15 2? angles, and a crystalline LNnT polymorph V, characterized in that it displays X-ray powder diffraction reflections, based on a measurement using CuK? radiation, at 9.15, 10.26, 19.68, 26.06, 20.61 and 1 1.89 2? angles, are provided.
    Type: Grant
    Filed: December 18, 2013
    Date of Patent: November 14, 2017
    Assignee: GLYCOM A/S
    Inventors: Benjámin Podányi, Gyula Dekany
  • Hydrogen bond forming fluoro ketolides for treating diseases
    Patent number: 9815863
    Abstract: The invention described herein pertains to a novel macrolide antibacterial agent of formula (I): A-L-Q, as defined herein, and pharmaceutically acceptable salts, solvates, and hydrates thereof. Inter alia, the new macrolide antibacterial agent is active against a number of bacterial species, including resistant species.
    Type: Grant
    Filed: September 9, 2011
    Date of Patent: November 14, 2017
    Assignee: CEMPRA PHARMACEUTICALS, INC.
    Inventor: David E. Pereira
  • Substituted nucleosides, nucleotides and analogs thereof
    Patent number: 9815864
    Abstract: Disclosed herein are nucleosides, nucleotides and analogs thereof, pharmaceutical compositions that include one or more of nucleosides, nucleotides and analogs thereof, and methods of synthesizing the same, of the Formula (I). Also disclosed herein are methods of ameliorating and/or treating a disease and/or a condition, including an infection from a norovirus, with a nucleoside, a nucleotide and an analog thereof.
    Type: Grant
    Filed: June 24, 2014
    Date of Patent: November 14, 2017
    Assignee: Alios BioPharma, Inc.
    Inventors: Leonid Beigelman, Jerome Deval, Zhinan Jin
  • Preparations of hydrophobic therapeutic agents, methods of manufacture and use thereof
    Patent number: 9815865
    Abstract: The present invention further provides method of preparing nanocrystals or microcrystals of a hydrophobic therapeutic agent such as fluticasone or triamcinolone, pharmaceutical compositions (e.g., topical or intranasal compositions) thereof and methods for treating and/or preventing the signs and/or symptoms of disorders such as blepharitis, meibomian gland dysfunction or skin inflammation or a respiratory disease (e.g., asthma).
    Type: Grant
    Filed: November 13, 2013
    Date of Patent: November 14, 2017
    Assignee: Nicox Ophthalmics, Inc.
    Inventors: Shikha P. Barman, Ritesh Vasudevan Thekkedath, Koushik Barman, Thomas Cavanagh, Tian Hao, Thomas Bovard Leland
  • Peptides that bind to epithelial cell adhesion molecule
    Patent number: 9815866
    Abstract: [Problem to be Solved] An object of the present invention is to provide a novel peptide that has the high ability to bind to EpCAM, which can be easily prepared by a chemical synthesis method or a genetic engineering method. [Solution] The present inventors have improved a method for screening a phage library and thereby successfully screened for a peptide that has the higher ability to bind to EpCAM compared with publicly known peptides. The present inventors have also used an already disclosed peptide having the ability to bind to EpCAM as a lead compound to prepare diverse populations of derivatives thereof, from among which a peptide strongly binding to EpCAM has been selected. The obtained peptides exhibit at least 10 times higher ability to bind to EpCAM compared with publicly known peptides and as such, are effective for the detection or diagnosis of cancer cells.
    Type: Grant
    Filed: September 12, 2013
    Date of Patent: November 14, 2017
    Assignee: JAPANESE FOUNDATION FOR CANCER RESEARCH
    Inventors: Kiyotaka Shiba, Katsutoshi Kokubun, Kanako Suga
  • Peptide for inhibiting vascular endothelial growth factor receptor
    Patent number: 9815867
    Abstract: An object of the present invention is to provide a VEGFR2 inhibitor peptide having high specificity and available at a low cost.
    Type: Grant
    Filed: September 2, 2013
    Date of Patent: November 14, 2017
    Assignees: The University of Tokyo, Peptidream Inc.
    Inventors: Hiroshi Murakami, Takashi Kawakami, Takahiro Ishizawa, Hiroaki Suga, Patrick Reid
  • Peptides binding to parallel-stranded G-quadruplexes
    Patent number: 9815868
    Abstract: A peptide comprising or consisting of the amino acid sequence of SEQ ID NO:1 or a derivative thereof is provided. Also provided are conjugates of such a peptide, the use of the peptide or the conjugates as a medicament, and methods for the detection of parallel-stranded G-quadruplexes.
    Type: Grant
    Filed: May 20, 2014
    Date of Patent: November 14, 2017
    Assignee: Nanyang Technological University
    Inventors: Anh Tuan Phan, Brahim Heddi, Vee Vee Cheong, Herry Martadinata
  • SP-B and SP-C peptides, synthetic lung surfactants, and use thereof
    Patent number: 9815869
    Abstract: The present invention relates to synthetic lung surfactant compositions that include a novel surface active peptide and a phospholipid, including phospholipase-resistant phospho-glycerol derivatives, phospholipase-resistant phospho-choline derivatives, naturally occurring phospholipids, or a combination thereof. Uses of the surfactant compositions of the present invention to treat endogenous surfactant dysfunctional or deficient lung tissue and to deliver therapeutic agents are also disclosed.
    Type: Grant
    Filed: February 11, 2013
    Date of Patent: November 14, 2017
    Assignees: University of Rochester, Los Angeles Biomedical Research Institute at Harbor-UCLA Medical Center
    Inventors: Robert H. Notter, Alan J. Waring, Frans J. Walther, Larry M. Gordon, Zhengdong Wang
  • Monomeric and bright infrared fluorescent proteins
    Patent number: 9815870
    Abstract: The invention described herein features variants related to infrared fluorescent proteins, in particular to mutants of a phytochrome from the bacterium Bradyrhizobium sp. ORS278. The variants show approximately a ten-fold increase in brightness compared to other known infrared fluorescent proteins. The variants are monomeric, allowing them to be used as a protein tag without disrupting the function of the tagged protein of interest.
    Type: Grant
    Filed: January 30, 2014
    Date of Patent: November 14, 2017
    Assignee: THE REGENTS OF THE UNIVERSITY OF CALIFORNIA
    Inventors: Dan Yu, Xiaokun Shu
  • Genetic reprogramming of bacterial biofilms
    Patent number: 9815871
    Abstract: Described herein are methods and compositions relating to engineered curli fibers, e.g. CsgA polypeptide. In some embodiments, the methods and compositions described herein relate to functionalized biofilms.
    Type: Grant
    Filed: April 23, 2014
    Date of Patent: November 14, 2017
    Assignee: President and Fellows of Harvard College
    Inventors: Neel Satish Joshi, Peter Quoc Nguyen, Zsofia Magarian
  • Toxoid peptides derived from phenol soluble modulin, delta toxin, superantigens, and fusions thereof
    Patent number: 9815872
    Abstract: The present disclosure provides immunogenic compositions useful in prevention and treatment of Staphylococcus aureus infection. In particular, the disclosure provides delta toxin and phenol-soluble modulin peptides as well as mutants, fragments, variants or derivatives thereof. The disclosure further provides multivalent oligopeptides, fusion proteins comprising two or more staphylococcal proteins, e.g., DT, PSM, alpha hemolysin, leukocidin, superantigen, or any fragments, variants, derivatives, or mutants thereof fused together as a single polypeptide in any order.
    Type: Grant
    Filed: June 18, 2014
    Date of Patent: November 14, 2017
    Assignee: INTEGRATED BIOTHERAPEUTICS, INC.
    Inventors: Mohammad Javad Aman, Rajan Prasad Adhikari, Sergey Shulenin, Frederick Wayne Holtsberg, Hatice Karauzum
  • Method for recovering plant-derived proteins
    Patent number: 9815873
    Abstract: Methods of recovering plant-derived proteins or suprastructure proteins, are provided. The method may comprise obtaining a plant, or plant matter comprising apoplast-localized proteins, or suprastructure proteins, loosening the cell wall to produce a plant or plant matter having a loosened cell wall, thus allowing the release of apoplastic content through the cell wall to produce an apoplastic content fraction from the plant or plant matter, and recovering the apoplastic content fraction. The apoplastic content fraction comprises plant-derived proteins or suprastructure proteins.
    Type: Grant
    Filed: March 23, 2012
    Date of Patent: November 14, 2017
    Assignee: MEDICAGO INC.
    Inventors: Manon Couture, Dany Paquet, Louis-Philippe Vezina
  • Compositions comprising fibrous polypeptides and polysaccharides
    Patent number: 9815874
    Abstract: Isolated polypeptides are disclosed comprising an amino acid sequence encoding a monomer of a fibrous polypeptide attached to a heterologous polysaccharide binding domain. Composites comprising same, methods of generating same and uses thereof are all disclosed.
    Type: Grant
    Filed: February 1, 2016
    Date of Patent: November 14, 2017
    Assignees: Yissum Research Development Company of the Hebrew University of Jerusalem Ltd., CollPlantLtd.
    Inventors: Oded Shoseyov, Shaul Lapidot, Sigal Meirovitch, Daniel L. Siegel
  • Postsynaptically targeted chemodenervation agents and their methods of use
    Patent number: 9815875
    Abstract: Improved chemodenervation agents are provided comprising polypeptide ?-neurotoxins having high binding specificity and selectivity for the human muscular ?1 nAChR instead of the human neuronal ?7 nAChR, along with pharmaceutical compositions and methods of use.
    Type: Grant
    Filed: February 19, 2009
    Date of Patent: November 14, 2017
    Assignee: MYOCEPT INC.
    Inventors: Lars Erik Peters, Todd Lorenz
  • Chimeric inhibitor molecules of complement activation
    Patent number: 9815876
    Abstract: The present invention relates to novel chimeric molecules of ficolin-associated polypeptides, such as fusion polypeptides for the use in the treatment of conditions associated with inflammation, apoptosis, autoimmunity, coagulation, thrombotic or coagulopathic related diseases. The present invention further relates to nucleic acid molecules encoding such fusion polypeptides, vectors and host cells used in the production of the fusion polypeptides.
    Type: Grant
    Filed: March 4, 2011
    Date of Patent: November 14, 2017
    Assignee: Omeros Corporation
    Inventors: Peter Garred, Tina Hummelshoj Glue, Mikkel-Ole Skjodt
  • Controlled gene expression methods
    Patent number: 9815877
    Abstract: Methods and compositions for controlling gene expression are disclosed.
    Type: Grant
    Filed: March 13, 2013
    Date of Patent: November 14, 2017
    Assignee: The Children's Hospital of Philadelphia
    Inventors: Gerd Blobel, Wulan Deng
  • Use of PEDF-derived polypeptides for preventing and/or ameliorating skin aging
    Patent number: 9815878
    Abstract: A method for preventing and/or ameliorating skin aging in a subject includes administering to the subject in need of such treatments a synthetic peptide, which has an amino acid sequence that has 20-39 amino acid residues. The synthetic peptide has at least 20 consecutive residues that has at least 90% amino acid sequence identity to residues 11-30 of SEQ ID NO: 1.
    Type: Grant
    Filed: September 19, 2012
    Date of Patent: November 14, 2017
    Assignee: MacKay Memorial Hospital
    Inventors: Yeou-Ping Tsao, Tsung-Chuan Ho
  • Method for the purification of G-CSF
    Patent number: 9815879
    Abstract: The present invention relates to a method for obtaining recombinant granulocyte-colony stimulating factor (G-CSF), comprising at least one cation exchange chromatography and at least one hydrophobic interaction chromatography, wherein said two chromatographic steps are immediately consecutive in optional order. In particular, the present invention relates to a method for purifying G-CSF from a mixture of G-CSF and other proteins, comprising two cation exchange chromatography steps which are conducted before and after a hydrophobic interaction chromatography, respectively.
    Type: Grant
    Filed: July 14, 2006
    Date of Patent: November 14, 2017
    Assignee: Sandoz AG
    Inventors: Arndt Dietrich, Bernhard Janowski, Jörg Schäffner, Ulrich Kurt Blaschke
  • IL-22 Fc fusion proteins
    Patent number: 9815880
    Abstract: The invention relates to IL-22 polypeptides, IL-22 Fc fusion proteins and IL-22 agonists, composition comprising the same, methods of making and methods of using the composition for the treatment of diseases. The invention also relates to IL-22 receptor associated reagents and methods of use thereof.
    Type: Grant
    Filed: July 22, 2016
    Date of Patent: November 14, 2017
    Assignee: Genentech, Inc.
    Inventors: Justin Scheer, Wenjun Ouyang, Richard Vandlen, Philip E. Hass, Eric Gary Stefanich, Xiaoting Wang
  • Method of inducing labor or treating pre-eclampsia by administering relaxin analogs
    Patent number: 9815881
    Abstract: Human relaxin analogs, polypeptide compositions related thereto, as well as nucleotide compositions encoding the same, are provided.
    Type: Grant
    Filed: January 31, 2013
    Date of Patent: November 14, 2017
    Assignee: The Board of Trustees of the Leland Stanford Junior University
    Inventors: Jae-Il Park, Sheau Yu Hsu
  • Tumor targeted Tnf-related apoptosis inducing ligand fusion polypeptide, methods and uses therefor
    Patent number: 9815882
    Abstract: Fusion polypeptides comprising a TRAIL trimer and a targeting domain are disclosed. The targeting domain can be, in some embodiments, a sequence that binds MUC16, which is prevalent on some tumor cells such as pancreatic and ovarian tumor cells. A sequence that binds MUC 16 can be mesothelin or a MUC16-binding fragment thereof, such as amino acids 1-64 of mesothelin. A fusion polypeptide of the present teachings can induce apoptosis in a target cell such as a MUC16-expressing cancer cell. Also disclosed are nucleic acids encoding the fusion polypeptides, and methods of use of the fusion polypeptides and nucleic acids.
    Type: Grant
    Filed: July 13, 2015
    Date of Patent: November 14, 2017
    Assignee: Washington University
    Inventors: Dirk Spitzer, William G Hawkins
  • Inhibiting peptides derived from TREM-like transcript 1 (TLT-1) and uses thereof
    Patent number: 9815883
    Abstract: The present invention relates to polypeptides fragments derived from the protein TLT-1 and their uses for the treatment of inflammatory conditions and more particularly for the treatment of sepsis.
    Type: Grant
    Filed: April 29, 2015
    Date of Patent: November 14, 2017
    Assignees: Institut National de la Sante et de la Recherche Medicale (INSERM), UNIVERSITE DE LORRAINE
    Inventors: Sebastien Gibot, Marc Derive
  • ApoE peptide dimers and uses thereof
    Patent number: 9815884
    Abstract: The present invention provides novel pharmaceutical compositions comprising ApoE-derived peptide dimers. In particular, the ApoE peptide dimers of the invention comprise at least two ApoE mimetic domains and can comprise one or more protein transduction domains. Methods of treating various conditions, such as cancer, inflammatory conditions, and neurodegenerative diseases, by administering the pharmaceutical compositions of the invention are also disclosed.
    Type: Grant
    Filed: March 20, 2015
    Date of Patent: November 14, 2017
    Assignee: Cognosci, Inc.
    Inventors: Michael P. Vitek, Dale J. Christensen
  • Inducible mutagenesis of target genes
    Patent number: 9815885
    Abstract: The present invention relates generally to mutagenesis of target genes that takes advantage of the natural mutagenic capabilities of B cells, and enhances those capabilities by bringing the process of diversification under control. The invention provides a method for rapidly and inducibly generating point mutations and other types of diversification in expressed genes, such as antibody genes. This method can be coupled with selection to identify B cell clones that produce, for example, antibodies of high affinity or specificity. The diversification process can be modulated, accelerated, halted, switched between methods of mutagenesis and the like. The modulation of diversification in accordance with the invention is both inducible and reversible. The invention provides a means of rapid and feasible development of a repertoire of variant immunoglobulins and other polypeptides.
    Type: Grant
    Filed: December 23, 2015
    Date of Patent: November 14, 2017
    Assignee: UNIVERSITY OF WASHINGTON
    Inventors: Nancy Maizels, W. Jason Cummings, Munehisa Yabuki
  • Compositions and methods for the treatment of immunodeficiency
    Patent number: 9815886
    Abstract: The present invention relates to compositions and methods for the treatment of immunodeficiency (e.g., primary immunodeficiency disease). In particular, the invention provides human plasma immunoglobulin compositions containing select antibody titers specific for a plurality of respiratory pathogens, methods of identifying human donors and donor samples for use in the compositions, methods of manufacturing the compositions, and methods of utilizing the compositions (e.g., for prophylactic administration and/or therapeutic treatment (e.g., passive immunization (e.g., immune-prophylaxis))).
    Type: Grant
    Filed: January 8, 2015
    Date of Patent: November 14, 2017
    Assignee: ADMA BIOLOGICS, INC.
    Inventors: Adam S. Grossman, James Mond, Jerrold B. Grossman, Dov A. Goldstein
  • Monoclonal antibodies that neutralize a norovirus
    Patent number: 9815887
    Abstract: Monoclonal neutralizing antibodies are disclosed that specifically bind to a Norovirus. In some embodiments, the Norovirus is a genogroup II Norovirus or a Genogroup II Norovirus. In some embodiments, the Norovirus is Nowalk virus. In some embodiments, the monoclonal antibodies specifically bind VP1. Also disclosed are compositions including the disclosed antibodies, nucleic acids encoding these antibodies, expression vectors including the nucleic acids, and isolated host cells that express the nucleic acids. The antibodies and compositions disclosed herein can be used for detecting the presence of a Norovirus in a biological sample, or detecting a Norovirus infection. In addition, the neutralization ability of the disclosed antibodies makes them ideal for treating a subject with a Norovirus infection. Thus, disclosed are methods of treating and/or preventing these infections.
    Type: Grant
    Filed: November 22, 2016
    Date of Patent: November 14, 2017
    Assignee: The United States of America, as Represented by the Secretary, Department of Health and Human Services
    Inventors: Zhaochun Chen, Robert H. Purcell, Lisbeth Kim Green, Stanislav Sosnovtsev, Karin Bok
  • Therapeutic use of specific ligand in MSRV associated diseases
    Patent number: 9815888
    Abstract: A ligand includes each of the complementary-determining regions (CDRs) set forth in SEQ ID No. 1, SEQ ID No. 2, SEQ ID No. 3 SEQ ID No. 4, SEQ ID No. 5 and SEQ ID No. 6 or any sequence having either number of substituted aminoacids within said sequences as indicated in the following, from 0 to 3 in CDR1 (SEQ ID No.1), from 0 to 2 in CDR2 (SEQ ID No.2), from 0 to 2 in CDR3 (SEQ ID No.3), from 0 to 1 in CDR4 (SEQ ID No.4), from 0 to 4 in CDR5 (SEQ ID No.5), from 0 to 2 in CDR6 (SEQ ID No.6), or aminoacids substituted with other aminoacids having equivalent chemical functions and properties, within said sequences SEQ ID No. 1 to SEQ ID No. 6.
    Type: Grant
    Filed: December 2, 2016
    Date of Patent: November 14, 2017
    Assignee: GENEURO SA
    Inventors: Corinne Bernard, Alois Bernhardt Lang, Herve Perron, Jean-Baptiste Bertrand
  • Antibodies for prevention and treatment of diseases caused by clostridium difficile
    Patent number: 9815889
    Abstract: The present invention relates to an antibody having specificity for an immunogenic determinant consisting of the pentasaccharide repeating unit of the Clostridium difficile glycopolymer PS-I: ?-L-Rhap-(1?3)-?-D-Glcp-(1?4)-[?-L-Rhap-(1?3)]-?-D-Glcp-(1?2)-?-D-Glcp or a fragment thereof. Said antibody is able to prevent and treat diseases caused by C. difficile. The present invention further pertains to a method of treating or preventing a disease caused by the pathogen Clostridium difficile, which comprises administering to a subject said antibody or a vaccine composition comprising said antibody.
    Type: Grant
    Filed: December 10, 2015
    Date of Patent: November 14, 2017
    Assignee: Max-Planck-Gesellschaft zur Foerderung der Wissenschaften e.V.
    Inventors: Peter H. Seeberger, Christopher E. Martin, Felix Broecker, Chakkumkal Anish
  • Antibodies to the C3d fragment of complement component 3
    Patent number: 9815890
    Abstract: The present invention relates to methods and materials for modulating the complement alternative pathway (CAP), the complement classical pathway (CCP), the complement lectin/mannose pathway (CMP), or combinations thereof, as well as methods and materials for targeting diagnostic, prophylactic and therapeutic agents to localized areas of tissue within the body where they may more directly exert their effects upon the intended target cells or tissue, with reduced, associated systemic effects compared with administration of the same or similar agents in an untargeted, systemic manner. The methods and materials of the present invention may therefore allow for increased efficacy, lower threshold effective dosages and/or lower effective maintenance doses, and/or reduced associated undesired or adverse effects in terms of frequency or severity of occurrence, or both.
    Type: Grant
    Filed: June 22, 2011
    Date of Patent: November 14, 2017
    Assignee: The Regents of the University of Colorado, a Body Corporate
    Inventors: V. Michael Holers, Joshua M. Thurman, Liudmila Kulik, Stephen Tomlinson
  • Monospecific polypeptide reagents
    Patent number: 9815891
    Abstract: The present invention relates to a novel antigen-binding protein construct or “modubody”, which contains at least three functional single domain modules of an antibody. The modubodies contain a domain from the heavy chain variable region of an antibody (VH), a domain from the light chain variable region of an antibody (VL) and bind monospecifically to an antigen. The modubodies further contain a domain from the constant region of antibodies. The modubodies can be used for diagnostic or therapeutic purposes.
    Type: Grant
    Filed: September 9, 2015
    Date of Patent: November 14, 2017
    Inventor: Robert Poppe
  • Multimeric constructs
    Patent number: 9815892
    Abstract: Multimeric fusion proteins of an Ig-like domain of Flt-1 are rendered functional by inclusion of a linker moiety. Vectors encoding the fusion proteins and host cells expressing the fusion proteins can be used therapeutically to block neovascularization in individuals with pathological conditions related to neovascularization. Such conditions include age-related macular degeneration, cancer, psoriasis, proliferative diabetic retinopathy, asthma, uveitis, osteoarthritis, and rheumatoid arthritis. The same means of multimerization used for an Iglike domain of Flt-1, i.e., a linker and a multimerization domain, can be used for other polypeptides, including extracellular receptors, antibody variable regions, cytokines, chemokines, and growth factors.
    Type: Grant
    Filed: January 31, 2014
    Date of Patent: November 14, 2017
    Assignee: Genzyme Corporation
    Inventors: Abraham Scaria, Peter Pechan, Samuel Wadsworth
  • Anti-VEGF antibodies and their uses
    Patent number: 9815893
    Abstract: The present disclosure relates to antibodies directed to vascular endothelial growth factor (“VEGF”) and uses of such antibodies, for example to treat diseases associated with the activity and/or overproduction of VEGF.
    Type: Grant
    Filed: November 27, 2013
    Date of Patent: November 14, 2017
    Assignee: AbbVie Biotherapeutics Inc.
    Inventor: Yoshiko Akamatsu
  • Use of reslizumab to treat moderate to severe eosinophilic asthma
    Patent number: 9815894
    Abstract: Disclosed herein are methods of treating moderate to severe eosinophilic asthma in a patient comprising administering a therapeutically effective dose of reslizumab to a patient whose symptoms are inadequately controlled with a current asthma therapeutic and wherein the patient's blood eosinophil levels are equal to or greater than 400/?L.
    Type: Grant
    Filed: August 28, 2015
    Date of Patent: November 14, 2017
    Assignee: Cephalon, Inc.
    Inventors: Christopher O'Brien, James Zangrilli, Tushar Shah
  • Methods of reducing basophil levels
    Patent number: 9815895
    Abstract: The present invention relates to a method of reducing the numbers of eosinophils in a human subject comprising administration to a subject an IL-5R binding molecule that comprises (a) a region that specifically binds to the IL-5R and (b) an immunoglobulin Fc region. In a specific embodiment, a method of the invention reduces the number of eosinophils in blood, bone marrow, gastrointestinal tract (e.g. esophagus, stomach, small intestine and colon), or lung.
    Type: Grant
    Filed: July 3, 2013
    Date of Patent: November 14, 2017
    Assignees: BIOWA, INC., ASTRAZENECA AB
    Inventors: Masamichi Koike, George L. Spitalny, Alistair Wheeler, Barbara White
  • Monoclonal antibody STRO-4
    Patent number: 9815896
    Abstract: The present invention relates to a monoclonal antibody designated STRO-4 which specifically binds human and ovine HSP-90beta and its use for enriching multipotential cells such as mesenchymal precursor cells (MPCs).
    Type: Grant
    Filed: July 9, 2015
    Date of Patent: November 14, 2017
    Assignee: ANGIOBLAST SYSTEMS, INC
    Inventors: Stan Gronthos, Andrew Christopher William Zannettino
  • Antibodies directed against programmed death-1 (PD-1)
    Patent number: 9815897
    Abstract: The invention relates to an isolated immunoglobulin heavy chain polypeptide and an isolated immunoglobulin light chain polypeptide that bind to a programmed death-1 (PD-1) protein. The invention provides a PD-1-binding agent that comprises the aforementioned immunoglobulin heavy chain polypeptide and immunoglobulin light chain polypeptide. The invention also provides related vectors, compositions, and methods of using the PD-1-binding agent to treat a cancer or an infectious disease.
    Type: Grant
    Filed: May 2, 2014
    Date of Patent: November 14, 2017
    Assignee: AnaptysBio, Inc.
    Inventors: David J. King, Marilyn Kehry
  • Antibody molecules to PD-1 and uses thereof
    Patent number: 9815898
    Abstract: Antibody molecules that specifically bind to PD-1 are disclosed. The anti-PD-1 antibody molecules can be used to treat, prevent and/or diagnose cancerous or infectious conditions and disorders.
    Type: Grant
    Filed: May 15, 2017
    Date of Patent: November 14, 2017
    Assignees: Novartis AG, PRESIDENT AND FELLOWS OF HARVARD COLLEGE, DANA-FARBER CANCER INSTITUTE, INC.
    Inventors: Gordon James Freeman, Arlene Helen Sharpe, Walter A. Blattler, Jennifer Marie Mataraza, Catherine Anne Sabatos-Peyton, Hwai Wen Chang, Gerhard Johann Frey
  • Antibody targeting osteoclast-related protein siglec-15
    Patent number: 9815899
    Abstract: To provide a method of detecting abnormal bone metabolism by using a gene strongly expressed in an osteoclast; a method of screening a compound having a therapeutic and/or preventive effect on abnormal bone metabolism; and a pharmaceutical composition for treating and/or preventing abnormal bone metabolism. Provision of a method of detecting abnormal bone metabolism by using the expression of human Siglec-15 gene as an index; a pharmaceutical composition containing an antibody which specifically recognizes human Siglec-15 and has an activity of inhibiting osteoclast formation; and the like.
    Type: Grant
    Filed: August 14, 2015
    Date of Patent: November 14, 2017
    Assignee: Daiichi Sankyo Company, Limited
    Inventors: Yoshiharu Hiruma, Eisuke Tsuda
  • Monoclonal antibody which is specifically bound to TM4SF5 protein and use thereof
    Patent number: 9815900
    Abstract: The present invention relates to a novel monoclonal antibody which is specifically bound to a transmembrane 4 L six family member 5 (TM4SF5) protein. More particularly, the present invention relates to a monoclonal antibody which is specifically bound to a human TM4SF5 protein, to polynucleotides coding for the monoclonal antibody, to an expression vector comprising the nucleotides, to a transformant with the vector introduced thereto, to a method for preparing the monoclonal antibody, to a composition comprising the monoclonal antibody, to a method for treating liver fibrosis using the monoclonal antibody, to a method for treating cancer using the monoclonal antibody, to a method for inhibiting metastasis of cancer, to a method for diagnosing cancer using the monoclonal antibody and to a cancer diagnosis kit comprising the monoclonal antibody.
    Type: Grant
    Filed: February 3, 2015
    Date of Patent: November 14, 2017
    Assignees: Korea Research Institute of Bioscience and Biotechnology, SNU R&DB Foundation
    Inventors: Se Mi Kim, Sang Jick Kim, Hye Jin Min, Jin Myeong Song, Jung Weon Lee, Hye Jin Kim, HyeMi Ahn, InPyo Choi, JiHye Ryu
  • Treatment of cancer using a CD123 chimeric antigen receptor
    Patent number: 9815901
    Abstract: The invention provides compositions and methods for treating diseases associated with expression of CD123. The invention also relates to chimeric antigen receptor (CAR) specific to CD123, vectors encoding the same, and recombinant cells comprising the CD123 CAR. The invention also includes methods of administering a genetically modified cell expressing a CAR that comprises a CD123 binding domain.
    Type: Grant
    Filed: August 19, 2015
    Date of Patent: November 14, 2017
    Assignees: Novartis AG, The Trustees of the University of Pennsylvania
    Inventors: Jennifer Brogdon, Saar Gill, David Glass, Saad Kenderian, Andreas Loew, Joan Mannick, Michael C. Milone, Leon Murphy, David L. Porter, Marco Ruella, Yongqiang Wang, Qilong Wu, Jiquan Zhang
  • Humanized anti-CXCR5 antibodies, derivatives thereof and their uses
    Patent number: 9815902
    Abstract: The present invention relates to humanized antibodies that specifically bind to CXCR5 and can, for example, inhibit CXCR5 function. The invention also includes uses of the antibodies to treat or prevent CXCR5 related diseases or disorders.
    Type: Grant
    Filed: August 22, 2016
    Date of Patent: November 14, 2017
    Assignee: SANOFI
    Inventors: Renata Lee, Vincent Mikol, Elizabeth Allen, Norman Ruetsch, Beatrice Cameron, Thomas Oligino, Nicholas Baurin
  • DAC HYP compositions
    Patent number: 9815903
    Abstract: The present disclosure relates to compositions of daclizumab suitable for subcutaneous administration and methods of manufacturing thereof.
    Type: Grant
    Filed: May 4, 2017
    Date of Patent: November 14, 2017
    Assignee: AbbVie Biotherapeutics Inc.
    Inventors: Taymar E. Hartman, Paul W. Sauer, John E. Burky, Mark C. Wesson, Ping Y. Huang, Thomas J. Robinson, Braeden D. Partridge, J. Yun Tso
  • Pertuzumab variants and evaluation thereof
    Patent number: 9815904
    Abstract: The present application discloses variants of Pertuzumab. In particular, it discloses: an unpaired cysteine variant comprising Cys23/Cys88 unpaired cysteines in one or both variable light domains of Pertuzumab, an afucosylated variant of Pertuzumab, a low-molecular-weight-species (LMWS) of Pertuzumab, and a high-molecular-weight-species (HMWS) or Pertuzumab. The application further discloses the isolated variants, compositions, pharmaceutical compositions, and articles of manufacture comprising the variants, as well as methods of making and characterizing the variants and compositions thereof.
    Type: Grant
    Filed: April 15, 2014
    Date of Patent: November 14, 2017
    Assignee: Genetech, Inc.
    Inventors: Lynn A. Gennaro, Yung-Hsiang Kao, Yonghua Zhang
  • Compositions and methods for the diagnosis and treatment of tumor
    Patent number: 9815905
    Abstract: The present invention is directed to compositions of matter useful for the diagnosis and treatment of tumor in mammals and to methods of using those compositions of matter for the same.
    Type: Grant
    Filed: September 29, 2014
    Date of Patent: November 14, 2017
    Assignee: Genentech, Inc.
    Inventors: Paul Polakis, Jyoti Asundi, Ron Firestein, Robert F. Kelley, Krista McCutcheon
  • Method of inhibiting or treating cancer metastasis
    Patent number: 9815906
    Abstract: The present invention relates to the diagnosis and treatment of cancer, and specifically to a method of diagnosing the presence, status or metastasis of cancer by detecting plasma Hsp90? having the amino acid sequence of SEQ ID NO:1 as a tumor marker. In addition, the present invention also relates to a method for the treatment of cancer and metastasis.
    Type: Grant
    Filed: February 13, 2015
    Date of Patent: November 14, 2017
    Assignees: TSINGHUA UNIVERSITY, PROTGEN LTD.
    Inventors: Yongzhang Luo, Xiaomin Song, Xiaofeng Wang, Wei Zhuo, Guodong Chang, Yan Fu
  • Binding partners specific for vitamin D epimers
    Patent number: 9815907
    Abstract: Antibodies are raised against compounds of Formula (I) where Z is an immunogenic carrier. These compounds are capable of binding specifically to corresponding antibodies. The antibodies are specific for epimers of vitamin D. Antibodies in accordance with the principles described herein may be employed to minimize or eliminate 3-epimer cross-reactivity in assays for non-epimeric forms of vitamin D analytes. Over-estimation of total non-epimeric vitamin D analyte caused by the cross-reactivity of 3-epimer vitamin D with an antibody for vitamin D analyte can be substantially avoided employing, as blocking agents, antibodies prepared against immunogens that are a compound of the Formula (I) wherein Z is an immunogenic carrier.
    Type: Grant
    Filed: June 22, 2015
    Date of Patent: November 14, 2017
    Assignee: Siemens Healthcare Diagnostics Inc.
    Inventors: Manoj Sharma, Tatiana Mareeva, Yuriy Smirnov, William D. Bedzyk, Zhu Teng, Tie Quan Wei
  • Chimeric antigen receptors with an optimized hinge region
    Patent number: 9815908
    Abstract: The present invention relates to multi-functional proteins which comprise (i) a signal peptide, (ii) a target specific recognition domain, (iii) a linker region, connecting domain (ii) and domain (iv) which comprises a specific modified hinge region of the human CD8 alpha-chain, and (iv) an effector domain. The present invention furthermore relates to nucleic acids encoding the proteins, expression constructs for expressing the protein in a host cell and host cells. The proteins of the invention are chimeric antigen receptors with an optimized linker or hinge region that are suitable for generating target-specific effector cells, for use as a medicament, in particular in the treatment of cancer and in adoptive, target-cell specific immunotherapy.
    Type: Grant
    Filed: October 30, 2015
    Date of Patent: November 14, 2017
    Assignee: CHEMOTHERAPEUTISCHES FORSCHUNGSINSTITUT GEORG-SPEYER-HAUS
    Inventors: Kurt Schönfeld, Christiane Schönfeld, Winfried Wels
  • Readily isolated bispecific antibodies with native immunoglobulin format
    Patent number: 9815909
    Abstract: The invention relates to antigen-binding proteins or antibodies having heterodimers of heavy chains, i.e., two immunoglobulin heavy chains that differ by at least one or two amino acid(s) that allows for isolation of the antigen-binding protein based on a differential affinity of an immunoglobulin heavy chain and a modified/mutated immunoglobulin heavy chain toward an affinity reagent. The invention also relates antigen-binding proteins, including bispecific antibodies, having IgG CH1 regions with different affinities with respect to affinity reagent(s) that allows rapid isolation by differential binding of the IgG regions to the affinity reagent(s).
    Type: Grant
    Filed: March 13, 2013
    Date of Patent: November 14, 2017
    Assignee: NOVIMMUNE S.A.
    Inventors: Nicolas Fischer, Giovanni Magistrelli, Francois Rousseau, Krzysztof Masternak, Pauline Malinge
  • Surface modification of cellulose nanocrystals
    Patent number: 9815910
    Abstract: Hydrophobic CNCs were successfully prepared by grafting amine- and thiol terminated hydrocarbons to CNCs that have been previously coated with plant polyphenols. Hydrocarbons of various chain lengths can be used to tune the hydrophobicity of the modified CNCs. After the surface modification process, CNCs can be easily redispersed in nonpolar solvents highlighting the potential of the hydrophobic CNCs in, for example, CNC reinforced nanocomposites and non-aqueous formulations.
    Type: Grant
    Filed: June 22, 2015
    Date of Patent: November 14, 2017
    Assignee: MCMASTER UNIVERSITY
    Inventors: Zhen Hu, Emily Cranston